Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Mdxhealth Sa ADR (MDXH)

Mdxhealth Sa ADR (MDXH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,165
  • Shares Outstanding, K 1,560
  • Annual Sales, $ 70,190 K
  • Annual Income, $ -43,100 K
  • 60-Month Beta 1.39
  • Price/Sales 1.16
  • Price/Cash Flow N/A
  • Price/Book 0.15
Trade MDXH with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.30
  • Number of Estimates 3
  • High Estimate -0.27
  • Low Estimate -0.35
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.21 +34.39%
on 04/19/24
3.20 -7.19%
on 04/03/24
+0.04 (+1.37%)
since 04/02/24
3-Month
2.21 +34.39%
on 04/19/24
3.85 -22.86%
on 03/07/24
-0.90 (-23.26%)
since 02/02/24
52-Week
2.15 +38.14%
on 10/03/23
4.64 -35.99%
on 01/09/24
-0.56 (-15.86%)
since 05/02/23

Most Recent Stories

More News
PerkinElmer (PKI) Q1 Earnings Surpass Estimates

PerkinElmer (PKI) delivered earnings and revenue surprises of 2.02% and 1.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

PKI : 115.24 (-0.91%)
MDXH : 2.96 (+10.86%)
AMN Healthcare Services (AMN) Surpasses Q1 Earnings and Revenue Estimates

AMN Healthcare (AMN) delivered earnings and revenue surprises of 5.51% and 1.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AMN : 59.94 (+0.07%)
MDXH : 2.96 (+10.86%)
Premier, Inc. (PINC) Q3 Earnings Match Estimates

Premier, Inc. (PINC) delivered earnings and revenue surprises of 0% and 8.69%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

PINC : 21.22 (+0.76%)
MDXH : 2.96 (+10.86%)
Analysts Estimate Avantor, Inc. (AVTR) to Report a Decline in Earnings: What to Look Out for

Avantor, Inc. (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AVTR : 24.27 (-0.61%)
MDXH : 2.96 (+10.86%)
Elevance (ELV) to Divest Life & Disability Business to StanCorp

With the sale of the life and disability business, Elevance Health (ELV) is focusing on growing its more profitable operations.

ICLR : 304.03 (+0.80%)
MDXH : 2.96 (+10.86%)
ELV : 525.63 (+0.15%)
WGS : 19.67 (-5.98%)
HLS Therapeutics Announces Board Appointment

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets,...

OPTN : 0.8760 (-3.55%)
MDXH : 2.96 (+10.86%)
HLS.TO : 4.66 (+0.22%)
Is a Surprise Coming for MDxHealth (MDXH) This Earnings Season?

MDxHealth (MDXH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

MDXH : 2.96 (+10.86%)
MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings

NEWS RELEASE – REGULATED INFORMATION 

MDXH : 2.96 (+10.86%)
MDxHealth Announces Favorable Draft Medicare Coverage for the SelectMDx for Prostate Cancer Test

Press release

MDXH : 2.96 (+10.86%)
MDxHealth Announces its Ordinary and Extraordinary General Shareholders’ Meetings

NEWS RELEASE – REGULATED INFORMATION

MDXH : 2.96 (+10.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

MDxHealth SA is a healthcare company which provides actionable molecular diagnostic information for diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation and other molecular technologies and assist physicians with the diagnosis of cancer. MDxHealth SA is headquartered...

See More

Key Turning Points

3rd Resistance Point 2.94
2nd Resistance Point 2.82
1st Resistance Point 2.75
Last Price 2.96
1st Support Level 2.56
2nd Support Level 2.44
3rd Support Level 2.37

See More

52-Week High 4.64
Fibonacci 61.8% 3.69
Fibonacci 50% 3.39
Fibonacci 38.2% 3.10
Last Price 2.96
52-Week Low 2.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar